ArticleHistochemistry and cell biology2012
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab.
Article in Histochemistry and cell biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.Journal of molecular histology · 2023Article
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- Vaginal necrosis: A rare late toxicity after radiation therapy.Gynecologic oncology · 2021Review
- Evaluation ofFrontiers in oncology · 2021Article
- Endothelial cells in colorectal cancer.World journal of gastrointestinal oncology · 2019Review
- Restriction of drug transport by the tumor environment.Histochemistry and cell biology · 2018Review
- Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer.Cancer management and research · 2018Article
- The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy.Frontiers in oncology · 2018Review
- Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.International journal of molecular sciences · 2016Review
- Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer.Oncotarget · 2016Review
- Targeting metastasis.Nature reviews. Cancer · 2016Review
- A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.Oncology reports · 2016Article
- Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.Chinese journal of cancer · 2016Review
- Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy.Stem cells international · 2016Review
- Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.British journal of cancer · 2015Article
- Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels.British journal of cancer · 2014Article
- Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro.Vascular cell · 2014Article
- Nestin(+) tissue-resident multipotent stem cells contribute to tumor progression by differentiating into pericytes and smooth muscle cells resulting in blood vessel remodeling.Frontiers in oncology · 2014Article
- Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5.Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab-resistant tumor vessels were characterized by an increased vessel diameter and normalization of vascular structures by the recruitment of mature pericytes and smooth muscle cells. Here, we analyzed human liver metastases which were taken at clinical relapse in patients with colorectal adenocarcinoma treated with anti-angiogenic therapy using the humanized monoclonal anti-VEGF bevacizumab. Tumor vessels which are resistant to anti-VEGF therapy are increased in size and characterized by a normalization of the vascular bed. These results were confirmed using NOD SCID mice as animal model and xenograft transplantation of human PC-3 prostate carcinoma cells in combination with bevacizumab treatment. Our results confirmed that anti-angiogenic therapy results in enhanced vascular remodeling by vascular stabilization. This process is apparently accompanied by enhanced necrosis of tumor tissue. These processes interfere with the efficacy of anti-angiogenic therapy because of reduced susceptibility of stabilized vessels by this therapy. These results demonstrate the importance for the development of second generation anti-angiogenic combination therapy concepts to rule out the balance between vascular stabilization followed by a possible de-stabilization making the remained vessels susceptible to a second wave of anti-angiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.